Brown Kevin A, Lambert Laurie J, Brophy James M, Nasmith James, Rinfret Stéphane, Segal Eli, Kouz Simon, Ross Dave, Harvey Richard, Maire Sébastien, Boothroyd Lucy J, Bogaty Peter
Institut national d'excellence en santé et en services sociaux (INESSS), Montréal, Québec, Canada.
McGill University Health Center, Montréal, Québec, Canada.
PLoS One. 2014 Aug 21;9(8):e104874. doi: 10.1371/journal.pone.0104874. eCollection 2014.
Many patients with ST-elevation myocardial infarction (STEMI) do not receive reperfusion therapy and are known to have poorer outcomes. We aimed to perform the first population-level, integrated analysis of clinical, ECG and hospital characteristics associated with non-receipt of reperfusion therapy in patients with STEMI.
This systematic evaluation of STEMI care in 82 hospitals in Quebec included all patients with a discharge diagnosis of myocardial infarction, presenting with characteristic symptoms and an ECG showing STEMI as attested by at least one of two study cardiologists or left bundle branch block (LBBB). Excluding LBBB, an ECG was considered a definite STEMI diagnosis if both cardiologists scored 'certain STEMI' and ambiguous if one scored 'uncertain' or 'not STEMI'. Centers were classified according to accessibility to primary percutaneous coronary intervention (PPCI): 1) on-site PPCI; 2) routine transfer for PPCI; 3) varying mix of PPCI transfer and on-site fibrinolysis; and 4) routine on-site fibrinolysis. Of 3730 STEMI/LBBB patients, 812 (21.8%) did not receive reperfusion therapy. In multivariate analysis, likelihood of no reperfusion therapy was a function of PPCI accessibility (odds ratio [OR] for fibrinolysis versus PPCI centers = 3.1; 95% CI: 2.2-4.4), presence of LBBB (OR = 24.1; 95% CI: 17.8-32.9) and an ECG ambiguous for STEMI (OR = 4.1; 95% CI: 3.3-5.1). When the ECG was ambiguous, likelihood of no reperfusion therapy was highest in hospitals most distant from PPCI centers.
ECG diagnostic ambiguity, LBBB and PPCI accessibility are important predictors of not receiving reperfusion therapy, suggesting opportunities for improving outcomes.
许多ST段抬高型心肌梗死(STEMI)患者未接受再灌注治疗,且已知其预后较差。我们旨在对STEMI患者未接受再灌注治疗相关的临床、心电图和医院特征进行首次人群水平的综合分析。
对魁北克82家医院的STEMI护理进行的这项系统评估纳入了所有出院诊断为心肌梗死、出现特征性症状且心电图显示STEMI的患者,该心电图由两名研究心脏病专家中的至少一人证实或为左束支传导阻滞(LBBB)。排除LBBB后,如果两名心脏病专家均将心电图评为“肯定STEMI”,则该心电图被视为明确的STEMI诊断;如果一人评为“不确定”或“非STEMI”,则该心电图为不明确。根据初级经皮冠状动脉介入治疗(PPCI)的可及性对中心进行分类:1)现场PPCI;2)常规转至PPCI;3)PPCI转院和现场纤溶治疗的不同组合;4)常规现场纤溶治疗。在3730例STEMI/LBBB患者中,812例(21.8%)未接受再灌注治疗。在多变量分析中,未接受再灌注治疗的可能性是PPCI可及性的函数(纤溶治疗中心与PPCI中心的比值比[OR]=3.1;95%CI:2.2-4.4)、LBBB的存在(OR=24.1;95%CI:17.8-32.9)以及STEMI心电图不明确(OR=4.1;95%CI:3.3-5.1)。当心电图不明确时,距离PPCI中心最远的医院中未接受再灌注治疗的可能性最高。
心电图诊断不明确、LBBB和PPCI可及性是未接受再灌注治疗的重要预测因素,提示改善预后的机会。